Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Injection in Patients With Recurrent Malignant Lymphoma

NCT03316144 is registered in ClinicalTrials.gov with Shanghai Junshi Bioscience Co., Ltd. as lead sponsor.

NCT NCT03316144
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03316144 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Injection in Patients With Recurrent Malignant Lymphoma
Lead sponsor
Shanghai Junshi Bioscience Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
July 12, 2017
Completion date
December 30, 2019
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant lymphoma